Trimethoprim-sulfamethoxazole.
The antimicrobial combination of trimethoprim and sulfamethoxazole is active in vitro against a variety of gram-positive and gram-negative bacteria. Clinically, it is useful for treatment and prophylaxis of various infections of the genitourinary tract and certain infections of the respiratory and gastrointestinal tracts. Trimethoprim-sulfamethoxazole by itself or in combination with other antimicrobial agents is effective for most Nocardia asteroides infections. It is the antimicrobial agent of choice for Pneumocystis carinii pneumonia. The drug is relatively nontoxic and available in oral and intravenous forms. The native compounds and the metabolites of trimethoprim and sulfamethoxazole are excreted primarily in the urine. When the creatinine clearance decreases to less than 30 ml/min, the dosage of trimethoprim-sulfamethoxazole should be adjusted.
D001424:Bacterial Infections / Q000188:drug therapy*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004405:Dysentery, Bacillary / Q000188:drug therapy; D006801:Humans; D009617:Nocardia Infections / Q000188:drug therapy; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013420:Sulfamethoxazole / Q000008:administration & dosage*; D014295:Trimethoprim / Q000008:administration & dosage*; D014552:Urinary Tract Infections / Q000188:drug therapy
D004338:Drug Combinations; D014295:Trimethoprim; D013420:Sulfamethoxazole